Q-omics provides the consensus-scored MS4A12 profile across patient tissues and cancer cell-line models. MS4A12 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MS4A12 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, MS4A12 RNA expression shows 8,948 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where MS4A12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MS4A12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MS4A12 survival associations across molecular data types. MS4A12 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MS4A12 RNA expression–survival associations across cancer types. High MS4A12 expression shows unfavorable associations in KIRC, UVM, ESCA, MESO and PCPG, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MS4A12 RNA expression.
This table summarizes MS4A12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MS4A12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MS4A12 shows lower tumor expression in COAD and READ and higher tumor expression in THCA and STAD. The COAD box plot shows higher MS4A12 RNA expression in normal versus tumor tissue (log2 FC = −5.940, t-test p < 0.001).
This table shows molecular features associated with MS4A12 in patient tissues and cancer cell lines. In patient samples, MS4A12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MS4A12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
